The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study
Abstract
Purpose We conducted a 5-year, double-blind, randomized, placebo-controlled study to determine whether salmon calcitonin nasal spray reduced the risk of new vertebral fractures in postmenopausal women with osteoporosis. Subjects and methods A total of 1,255 postmenopausal women with established osteoporosis were randomly assigned to receive salmon calcitonin nasal spray (100, 200, or 400 IU) or placebo daily. All participants received elemental calcium (1,000 mg) and vitamin D (400 IU) daily. Vertebral fractures were assessed with lateral radiographs of the spine. The primary efficacy endpoint was the risk of new vertebral fractures in the salmon calcitonin nasal spray 200-IU group compared with the placebo group. Results During 5 years, 1,108 participants had at least one follow-up radiograph. A total of 783 women completed 3 years of treatment, and 511 completed 5 years. The 200-IU dose of salmon calcitonin nasal spray significantly reduced the risk of new vertebral fractures by 33% compared with placebo [200 IU: 51 of 287, placebo: 70 of 270, relative risk (RR) = 0.67, 95% confidence interval (CI): 0.47- to 0.97, P = 0.03]. In the 817 women with one to five prevalent vertebral fractures at enrollment, the risk was reduced by 36% (RR = 0.64, 95% CI: 0.43- to 0.96, P = 0.03). The reductions in vertebral fractures in the 100-IU (RR = 0.85, 95% CI: 0.60- to 1.21) and the 400-IU (RR = 0.84, 95% CI: 0.59- to 1.18) groups were not significantly different from placebo. Lumbar spin…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The study found that a daily dose of 200 IU significantly reduced the risk of new vertebral fractures in the study population.”
From The Activity of Peptides of the Calcitonin Family in Bone (2019) · cites this paper as [35]
In the citing paper
“This is true for fracture patients with BMD in both the low bone mass and osteoporosis range [49–58].”
From Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014) · cites this paper as [54]
In the citing paper
“There are abundant data that patients with spine and hip fractures will have reduced fracture risk if treated with pharmacologic therapy.”
From Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014) · cites this paper as [54]
In the citing paper
“Calcitonin reduces vertebral fracture occurrence by about 30 % in those with prior vertebral fractures but has not been shown to reduce the risk of nonvertebral fractures [54, 79].”
From Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014) · cites this paper as [54]
In the citing paper
“Calcitonin reduces vertebral fracture occurrence by about 30 % in those with prior vertebral fractures but has not been shown to reduce the risk of nonvertebral fractures [54, 79].”
From Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014) · cites this paper as [54]
Citations
Cites
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Regression Models and Life-Tables
Cox, D. R. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_37 · Cited by 26,297
Littell, R. C. (1996) · Medical Entomology and Zoology · Cited by 10,547
Black, D. M., Cummings, S. R., Karpf, D. B., Cauley, J. A., Thompson, D. E., Nevitt, M. C., Bauer, D. C., Genant, H. K., Haskell, W. L., Marcus, R., et al. (1996) · The Lancet · doi:10.1016/s0140-6736(96)07088-2 · Cited by 3,846
Self-citationLiberman, U. A., Weiss, S. R., Bröll, J., Minne, H. W., Quan, H., Bell, N. H., Rodriguez-Portales, J., Downs, R. W., Dequeker, J., Favus, M., et al. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511303332201 · Cited by 2,288
Markers of bone resorption predict hip fracture in elderly women: The EPIDOS prospective study
Garnero, P., Hausherr, E., Chapuy, M.-C., Marcelli, C., Grandjean, H., Muller, C., Cormier, C., Bréart, G., Meunier, P. J., & Dr. Delmas, P. D. (1996) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650111021 · Cited by 989
Garnero, P. (1994) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.79.6.1693 · Cited by 707 · cited 1×
“Age (years) ,65 99 (32) 100 (32) 84 (27) 95 (30) 65–74 148 (48) 149 (47) 153 (48) 166 (53) $75 64 (21) 67 (21) 79 (25) 51 (16) Age (years) 68.”
The crippling consequences of fractures and their impact on quality of life
Cooper, C. (1997) · The American Journal of Medicine · doi:10.1016/s0002-9343(97)90022-x · Cited by 699 · cited 1×
“Although vertebral fractures are the usual presenting manifestation of osteoporosis (42) and are associated with substantial morbidity (43), fractures of the hip have greater morbidity, mortality, and cost (43).”
BackgroundGenant, H. K., Jergas, M., Palermo, L., Nevitt, M., Valentin, R. S., Black, D., & Cummings, S. R. (1996) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650110716 · Cited by 643 · cited 2×
“Incident fractures were defined as a 20% or greater and greater than 4-mm decrease in any vertebral height (vs previous radiograph) by quantitative morphometry, as well as a change in the fracture grade from 0 to 1 or greater by semiquantitative evaluation, with adjudication in discrepant cases as outlined above (28,2…”
MethodSelf-citationChavassieux, P. M., Arlot, M. E., Reda, C., Wei, L., Yates, A. J., & Meunier, P. J. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119668 · Cited by 523 · cited 2×
“An improvement in bone mineralization (30,53) Figure 3.”
Background
Research works printed but not linked: 3
- Raisz, 1983, Bone metabolism and its hormonal regulation, Triangle, 22, 83
- Chambers, 1988, The effect of calcitonin on the osteoclast, Triangle, 27, 53
- Gundberg, 1998, Biology, physiology, and clinical chemistry of osteocalcin, J Clin Ligand Assay, 21, 128
Cited by
Neer, R. M., Arnaud, C. D., Zanchetta, J. R., Prince, R., Gaich, G. A., Reginster, J.-Y., Hodsman, A. B., Eriksen, E. F., Ish-Shalom, S., Genant, H. K., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105103441904 · Cited by 4,602
Self-citationClinician’s Guide to Prevention and Treatment of Osteoporosis
Cosman, F., de Beur, S. J., LeBoff, M. S., Lewiecki, E. M., Tanner, B., Randall, S., & Lindsay, R. (2014) · Osteoporosis International · doi:10.1007/s00198-014-2794-2 · Cited by 4,149
Self-citationOnce-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis
Black, D. M., Delmas, P. D., Eastell, R., Reid, I. R., Boonen, S., Cauley, J. A., Cosman, F., Lakatos, P., Leung, P. C., Man, Z., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa067312 · Cited by 2,986
European guidance for the diagnosis and management of osteoporosis in postmenopausal women
Kanis, J. A., McCloskey, E. V., Johansson, H., Cooper, C., Rizzoli, R., Reginster, J.-Y., & on behalf of the Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the Committee of Scientific Advisors of the International Osteoporosis Foundation (IOF) (2013) · Osteoporosis International · doi:10.1007/s00198-012-2074-y · Cited by 2,948
Protein Therapeutics: A Summary and Pharmacological Classification
Leader, B., Baca, Q. J., & Golan, D. E. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2399 · Cited by 2,161
Metadata
- Authors
- Chesnut, C. H., Silverman, S., Andriano, K., Genant, H., Gimona, A., Harris, S., Kiel, D., LeBoff, M., Maricic, M., Miller, P., Moniz, C., Peacock, M., Richardson, P., Watts, N., & Baylink, D.
- Affiliations
- University of Washington (US)
- University of California, Los Angeles (US)
- Novartis (United States) (US)
- University of California, San Francisco (US)
- Novartis (Switzerland) (CH)
- Rhode Island Hospital (US)
- Brigham and Women's Hospital (US)
- University of Arizona (US)
- Colorado Center for Bone Research (US)
- King's College Hospital (GB)
- Emory Clinic (US)
- Jerry L. Pettis Memorial VA Medical Center (US)
- Corresponding author
- Chesnut, Charles H
- ORCID
- Venue
- The American Journal of Medicine
- Publisher
- Elsevier BV
- Published
- 2000-09
- Volume
- 109
- Issue
- 4
- Pages
- 267-276
- ISSN
- 0002-9343 (ISSN-L)
- OpenAlex
- W1992931986
- Semantic Scholar
- b05f6e717772958e59575400a48dd62811c32636
- Cited by
- 1,122
- References
- 52
- Citations by year
- 2026: 6 · 2025: 12 · 2024: 10 · 2023: 15 · 2022: 17 · 2021: 21 · 2020: 23 · 2019: 19 · 2018: 26 · 2017: 16 · 2016: 23 · 2015: 33 · 2014: 31 · 2013: 49 · 2012: 44
- FWCI
- 70.82
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- Locations
- The American Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Cedars-Sinai Medical Center
- Topics
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Vitamin D Research Studies
- Keywords
- salmon calcitonin, nasal spray, osteoporosis, postmenopausal women, vertebral fractures, fracture prevention, bone mineral density, bone turnover, calcium and vitamin D supplementation, dose-response relationship, lumbar spine, hip fracture, treatment discontinuation, adverse effects, drug safety, cost-effectiveness, quality of life
- MeSH terms
- Aged, Analysis of Variance, Calcitonin, Double-Blind Method, Female, Fractures, Spontaneous, Humans, Middle Aged, Nasal Cavity, Reference Values, Bone Density, Osteoporosis, Postmenopausal, Chi-Square Distribution, Spinal Fractures, Treatment Outcome, Secondary Prevention
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. https://app.cochat.ai/papers/10.1016/s0002-9343(00)00490-3
- The paper
- Chesnut, C. H., Silverman, S., Andriano, K., Genant, H., Gimona, A., Harris, S., Kiel, D., LeBoff, M., Maricic, M., Miller, P., Moniz, C., Peacock, M., Richardson, P., Watts, N., & Baylink, D. (2000). A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. The American Journal of Medicine. https://doi.org/10.1016/s0002-9343(00)00490-3
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.